| Autor: |
Den, R B, Santiago-Jimenez, M, Alter, J, Schliekelman, M, Wagner, J R, Renzulli II, J F, Lee, D I, Brito, C G, Monahan, K, Gburek, B, Kella, N, Vallabhan, G, Abdollah, F, Trabulsi, E J, Lallas, C D, Gomella, L G, Woodlief, T L, Haddad, Z, Lam, L L C, Deheshi, S, Wang, Q, Choeurng, V, du Plessis, M, Jordan, J, Parks, B, Shin, H, Buerki, C, Yousefi, K, Davicioni, E, Patel, V R, Shah, N L |
| Zdroj: |
Prostate Cancer and Prostatic Diseases; December 2016, Vol. 19 Issue: 4 p374-379, 6p |
| Abstrakt: |
Background:Currently, there are multiple commercially available RNA-based biomarkers that are Medicare approved and suggested for use by the National Comprehensive Cancer Network guidelines. There is uncertainty as to which patients benefit from genomic testing and for whom these tests should be ordered. Here, we examined the correlation patterns of Decipher assay to understand the relationship between the Decipher and patient tumor characteristics.Methods:De-identified Decipher test results (including Decipher risk scores and clinicopathologic data) from 2 342 consecutive radical prostatectomy (RP) patients tested between January and September 2015 were analyzed. For clinical testing, tumor specimen from the highest Gleason grade was sampled using a 1.5 mm tissue punch. Decipher scores were calculated based on a previously locked model. Correlations between Decipher score and clinicopathologic variables were computed using Spearman’s rank correlation. Mixed-effect linear models were used to study the association of practice type and Decipher score. The significance level was 0.05 for all tests.Results:Decipher score had a positive correlation with pathologic Gleason score (PGS; r=0.37, 95% confidence interval (CI) 0.34−0.41), pathologic T-stage (r=0.31, 95% CI 0.28−0.35), CAPRA-S (r=0.32, 95% CI 0.28−0.37) and patient age (r=0.09, 95% CI 0.05-0.13). Decipher reclassified 52%, 76% and 40% of patients in CAPRA-S low-, intermediate- and high-risk groups, respectively. We detected a 28% incidence of high-risk disease through the Decipher score in pT2 patients and 7% low risk in pT3b/pT4, PGS 8−10 patients. There was no significant difference in the Decipher score between patients from community centers and those from academic centers (P=0.82).Conclusions:Although Decipher correlated with baseline tumor characteristics for over 2 000 patients, there was significant reclassification of tumor aggressiveness as compared to clinical parameters alone. Utilization of the Decipher genomic classifier can have major implications in assessment of postoperative risk that may impact physician-patient decision making and ultimately patient management. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
Full text from SpringerLink